Alliancebernstein L.P. Glycomimetics Inc Transaction History

Alliancebernstein L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 30, 2021	SELL	$2.16 - $3.18 $157,248 - $231,504	-72,800 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$3.07 - $5.0 $7,982 - $13,000	-2,600 Reduced 3.45%	72,800 $223,000
Q2 2020 Aug 13, 2020	BUY	$2.06 - $3.76 $56,856 - $103,776	27,600 Added 57.74%	75,400 $284,000
Q1 2020 May 14, 2020	BUY	$1.83 - $5.41 $7,686 - $22,722	4,200 Added 9.63%	47,800 $109,000
Q3 2019 Nov 14, 2019	BUY	$2.8 - $12.85 $19,880 - $91,235	7,100 Added 19.45%	43,600 $188,000
Q2 2019 Aug 14, 2019	BUY	$10.6 - $13.12 $44,520 - $55,104	4,200 Added 13.0%	36,500 $435,000
Q1 2019 May 14, 2019	BUY	$9.96 - $13.44 $39,840 - $53,760	4,000 Added 14.13%	32,300 $402,000
Q4 2018 Feb 13, 2019	BUY	$8.47 - $14.71 $49,126 - $85,318	5,800 Added 25.78%	28,300 $268,000
Q3 2018 Nov 08, 2018	BUY	$13.7 - $17.12 $94,530 - $118,128	6,900 Added 44.23%	22,500 $324,000
Q2 2018 Aug 13, 2018	BUY	$14.63 - $19.19 $228,228 - $299,364	15,600 New	15,600 $252,000

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.3M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.